• :::Home
  • HK Technologies
  • Nano-vesicles for Improving Drug’s Stability and Efficacy to Treat Chronic Diseases

Nano-vesicles for Improving Drug’s Stability and Efficacy to Treat Chronic Diseases

Overview

This is a new protective layer manufacturing technology with high encapsulation efficiency, which allows the control of the release and delivery of active pharmaceutical ingredients. It can prolong the therapeutic effect of drugs, increase the drug retention time in the body, and eventually reduce the dosage, systemic side effects and toxicity of the drugs.

  • Nano-vesicles for Improving Drug’s Stability and Efficacy to Treat Chronic Diseases
Commercialisation opportunities
technology licensing agreement
Problem addressed

The diabetes and asthma drugs will be quickly metabolized by the human body and the therapeutic effect of active pharmaceutical ingredients can only last for a short period.

Innovation
  • We have developed a new protective layer manufacturing technology with high encapsulation efficiency. Solid lipid vesicles are manufactured to encapsulate the drugs and serve as a drug delivery system.
  • This not only achieves a better drug delivery effect but also increases the effective time and stability of the drug. Our animal study demonstrated a slow transportation rate of pharmaceutical ingredients encapsulated in liposomes and showed that the rapid loss of drugs in the body is prevented.
Key impact
  • With this technolgoy, the frequency of drug administration, dosage, side effects of the drugs can be reduced.
  • Taking Salbutamol sulfate (SBS), a model asthma alleviating drug as an example, if this technology is applied, the therapeutic effect of SBS can be prolonged by 4 times, and patients only need to take the drug once a day. This will greatly reduce the inconvenience in patients' daily lives.
Application
  • The technology can be used to fabricate dehydrated lipid vesicles for drug delivery, such as: - encapsulating existing drugs for common chronic diseases like diabetes and asthma
  • fabricating aerosolized liposome carrier for pulmonary delivery of SBS
  • conjugating with targeting ligands to enrich site-specific therapeutic action

Patent

  • China Patent No. ZL 2014 1 0055853.5
  • Hong Kong Patent No. HK 1208626
  • Japan Patent No. JP 6305555
  • US Patent No. US 9,980,906
Hong Kong Baptist University (HKBU)

Aspiring to be a leading, research-led, liberal arts University in Asia, Hong Kong Baptist University is committed to conducting world-leading investigations that extends the frontiers of knowledge, tackles global challenges and benefits the community at home and abroad. 

Pursuing research excellence is one of the priorities of the University’s Institutional Strategic Plan 2018-2028. The University keeps enhancing its capacity and strength to produce world-class research with an aim to bring significant impact to the society. 

Enquiry